Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study

Patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) are insensitive to conventional chemotherapy and, therefore, have a poor prognosis. To evaluate the clinical efficacy and safety of low-dose decitabine in combination with small-dose CAG regimen (D-CAG regimen) in tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Liu, Xiaohong, Jia, Jinsong, Gong, Lizhong, Lu, Shengye, Wang, Jing, Huang, Xiao-jun, Jiang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Research Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594112/
https://www.ncbi.nlm.nih.gov/pubmed/36304522
http://dx.doi.org/10.1016/j.lrr.2022.100354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594112/
https://www.ncbi.nlm.nih.gov/pubmed/36304522
http://dx.doi.org/10.1016/j.lrr.2022.100354

Ejemplares similares